Icon (NASDAQ:ICLR) is scheduled to issue its quarterly earnings data before the market opens on Thursday, February 15th. Analysts expect the company to announce earnings of $1.41 per share for the quarter.
Icon (ICLR) opened at $109.55 on Tuesday. The company has a market cap of $5,920.00, a PE ratio of 21.27, a PEG ratio of 1.51 and a beta of 0.48. Icon has a 1-year low of $76.46 and a 1-year high of $124.48. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31.
An institutional investor recently raised its position in Icon stock. Vanguard Group Inc. boosted its position in shares of Icon Plc (NASDAQ:ICLR) by 19.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,545 shares of the medical research company’s stock after purchasing an additional 2,400 shares during the period. Vanguard Group Inc.’s holdings in Icon were worth $1,422,000 at the end of the most recent quarter. 89.66% of the stock is currently owned by hedge funds and other institutional investors.
ICLR has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Icon from a “hold” rating to a “buy” rating and set a $132.00 price objective for the company in a report on Tuesday, January 9th. KeyCorp reaffirmed a “buy” rating and set a $130.00 price objective on shares of Icon in a report on Thursday, January 11th. ValuEngine raised shares of Icon from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. SunTrust Banks reaffirmed a “buy” rating and set a $138.00 price objective on shares of Icon in a report on Sunday, October 29th. Finally, Barclays lifted their price target on shares of Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $124.55.
TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/13/icon-iclr-to-release-quarterly-earnings-on-thursday.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.